|INDIA: Petri Dish for Pharmaceutical MNCs|
by Ann De Ron, Inter Press News Service
July 10th, 2006
Pharmaceutical multinationals, seeking to ramp up profits through cheap drug trials, are increasingly turning to India with its combination of a vast pool of poor, ignorant patients on the one hand and skilled medical personnel and fine research infrastructure on the other.
|US: Another Merck Drug Is Under Legal Attack|
by Molly Selvin, The Los Angeles Times
July 5th, 2006
As Merck & Co. defends itself against a deluge of litigation involving its pain reliever Vioxx, the pharmaceutical giant also is fielding the first of what could be another wave of lawsuits involving Fosamax, its second-biggest seller.
|US: Charities Tied to Doctors Get Drug Industry Gifts|
by Reed Abelson, The New York Times
June 28th, 2006
Around the country, doctors in private practice have set up tax-exempt charities into which drug companies and medical device makers are, with little fanfare, pouring donations — money that adds up to millions of dollars a year. And some medical experts see that as a big problem.
|US: Drug Firms a Danger to Health – Report|
by Sarah Boseley, The Guardian (UK)
June 26th, 2006
Drug companies are accused today of endangering public health through widescale marketing malpractices, ranging from covertly attempting to persuade consumers that they are ill to bribing doctors and misrepresenting the results of safety and efficacy tests on their products.
|US: Drug Prices Up Sharply This Year|
by Milt Freudenheim, The New York Times
June 21st, 2006
Prices of the most widely used prescription drugs rose sharply in this year's first quarter, just as the new Medicare drug coverage program was going into effect, according to separate studies issued yesterday by two large consumer advocacy groups.
|US: Drugs firm blocks cheap blindness cure
by Sarah Boseley, The Guardian
June 17th, 2006
A major drug company is blocking access to a medicine that is cheaply and effectively saving thousands of people from going blind because it wants to launch a more expensive product on the market.
|US: Lawyer: Merck Scrapped Study on Vioxx|
by Linda A. Johnson, The Associated Press
June 16th, 2006
Merck & Co. scrapped a planned study of the cardiac safety of Vioxx once it knew U.S. regulators were going to tone down their warning about heart risks for patients taking the painkiller, a plaintiff's lawyer argued Friday in a product liability trial.
|US: Grandmother Takes on Merck in Vioxx Trial|
by LINDA A. JOHNSON, Associated Press
June 5th, 2006
Drug maker Merck & Co. repeatedly tried to downplay the cardiac risks of its painkiller Vioxx, so user Elaine Doherty didn't know about them and couldn't control them before she suffered a heart attack after taking the drug, her lawyer told jurors as a product liability trial began Monday.
|US: Merck Admits a Data Error on Vioxx|
by Alex Berenson, New York Times
May 31st, 2006
In an admission that could undermine one of its core defenses in Vioxx-related lawsuits, Merck said yesterday that it had erred when it reported in early 2005 that a crucial statistical test showed that Vioxx caused heart problems only after 18 months of continuous use.
|US: FDA Warns Wyeth on Quality at Puerto Rico Plant|
May 30th, 2006
Possible contaminants in headache remedies, hormone replacement therapy and other pills made at Wyeth's (WYE.N: Quote, Profile, Research) plant in Puerto Rico have not been adequately checked out or corrected, the U.S. Food and Drug Administration said on Tuesday.
|US: Uh-oh, it's the shareholders|
by Bruce Meyerson, Chicago Sun-Times
May 21st, 2006
It happens only once a year, and yet so many headstrong corporate CEO's can't seem to cope with being in a room with shareholders for a few hours at the annual meeting.